Notice of AGM & Posting of Annual Report

Instem plc

02 June 2023

 

Instem plc

 ("Instem", or the "Company")

Notice of AGM

Posting of Annual Report

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it has posted to shareholders its Annual Report and Accounts for the year ended 31 December 2022, together with the Notice of Annual General Meeting which is to be held at the offices of the Company at 2 Diamond Way, Stone Business Park, Stone, Staffordshire, ST15 0SD on 27^th June 2023 at 2.30 p.m.

A copy of the Annual Report and Accounts and Notice of Annual General meeting is available on Instem's website.

For further information, please contact: Instem plc Via Walbrook Phil Reason, CEO Nigel Goldsmith, CFO Singer Capital Markets (Nominated Adviser & Broker) [phone] Peter Steel Alex Bond Stifel Nicolaus Europe Limited (Joint Broker) [phone] Ben Maddison Richard Short Walbrook Financial PR [phone] Tom Cooper [e-mail] Nick Rome Joe Walker

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

About eTRANSAFE

The "Enhancing TRANslational SAFEty Assessment through Integrative Knowledge Management (eTRANSAFE)" project develops an integrative data infrastructure and innovative computational methods and tools that aim to drastically improve the feasibility and reliability of translational safety assessment during the drug development process. This infrastructure will be underpinned by development of open standards and robust policies widely accepted by stakeholders, including regulatory agencies and international organisations.

The eTRANSAFE is a 5.5-year project, started on 1st September of 2017, funded by the Innovative Medicines Initiative 2 Joint Undertaking (IMI 2) together with the pharmaceutical industry, that aims to develop an advanced data integration infrastructure together with innovative computational methods to improve the security in drug development process.

 

END